Psychology works fact sheet: bipolar disorder. Canadian Psychology Association 2022. https://cpa.ca/psychology-works-fact-sheet-bipolar-disorder/
Oquendo MA, Galfalvy HC, Currier D, et al. Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. Am J Psychiatry. 2011;168(10):1050–6. https://doi.org/10.1176/appi.ajp.2011.11010163.
Geddes JR, Miklowitz DJ. Treatment of bipolar disorder. Lancet. 2013;381(9878):1672–82. https://doi.org/10.1016/S0140-6736(13)60857-0.
Gitlin M. Lithium side effects and toxicity: prevalence and management strategies. Int J Bipolar Disord. 2016;4(1):27. https://doi.org/10.1186/s40345-016-0068-y.
Meehan AD, Udumyan R, Kardell M, Landén M, Järhult J, Wallin G. Lithium-Associated Hypercalcemia: Pathophysiology, Prevalence, Management. World J Surg. 2018;42(2):415–24. https://doi.org/10.1007/s00268-017-4328-5.
Deedwania PC. Statins in chronic kidney disease: cardiovascular risk and kidney function. Postgrad Med. 2014;126(1):29–36.
Shulman KI, Sykora K, Gill S, et al. Incidence of delirium in older adults newly prescribed lithium or valproate: a population-based cohort study. J Clin Psychiatry. 2005;66(4):424–7. https://doi.org/10.4088/jcp.v66n0403.
Wilson LAM, White KM. Integrating complementary and alternative therapies into psychological practice: a qualitative analysis. Aust J Psychol. 2011;63(4):232–42.
Lembke A. Optimal dosing of lithium, valproic acid, and lamotrigine in the treatment of mood disorders. Primary Psychiatry. 2009;16(10):37.
Lithium Risk of Hypercalcemia and Hyperparathyroidism: For health professionals. Health Canada. Accessed September, 2020. https://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2014/37903a-eng.php.
Highlights of prescribing information. U.S. Food and Drug Administration. Accessed September, 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/017812s033,018421s032,018558s027lbl.pdf.
Lehmann SW, Forester BP. Bipolar disorder in older age patients: Springer; 2017.
Leo RJ, Sharma M, Chrostowski DA. A case of lithium-induced symptomatic hypercalcemia. Prim Care Companion J Clin Psychiatry. 2010;12(4). https://doi.org/10.4088/PCC.09l00917yel.
Aksakal N, Erçetin C, Özçınar B, Aral F, Erbil Y. Lithium-associated primary hyperparathyroidism complicated by nephrogenic diabetes insipidus. Ulus Cerrahi Derg. 2015;31(3):166–9. https://doi.org/10.5152/UCD.2014.2859.
Farford B, Presutti RJ, Moraghan TJ. Nonsurgical management of primary hyperparathyroidism. Mayo Clin Proc. 2007;82(3):351–5. https://doi.org/10.4065/82.3.351.
Fahy S, Lawlor BA. Discontinuation of lithium augmentation in an elderly cohort. Intern J Geriatric Psychiatry. 2001;16(10):1004–9.
Hardy BG, Shulman KI, Zucchero C. Gradual discontinuation of lithium augmentation in elderly patients with unipolar depression. J Clin Psychopharmacol. 1997;17(1):22–6.
Lieber I, Ott M, Öhlund L, et al. Lithium-associated hypothyroidism and potential for reversibility after lithium discontinuation: findings from the LiSIE retrospective cohort study. J Psychopharmacol. 2020;34(3):293–303.
Li W, Zhang Y, Bouley R, et al. Simvastatin enhances aquaporin-2 surface expression and urinary concentration in vasopressin-deficient Brattleboro rats through modulation of rho GTPase. Am J Physiol Renal Physiol. 2011;301(2):F309–18. https://doi.org/10.1152/ajprenal.00001.2011.
Procino G, Milano S, Carmosino M, et al. Combination of secretin and fluvastatin ameliorates the polyuria associated with X-linked nephrogenic diabetes insipidus in mice. Kidney Int. 2014;86(1):127–38. https://doi.org/10.1038/ki.2014.10.
Elie D, Segal M, Low NC, et al. Statins in the prevention of lithium-associated diabetes insipidus: preliminary findings. Kidney Int. 2015;4:862.
Rej S, Segal M, Low NC, et al. In this correspondence, preliminary data in 100 lithium users found that urine osmolality correlated with chronic kidney disease, diabetes mellitus, and hypothyroidism. We hypothesize that GSK-3β inhibition is a potential mechanism for lithium-associated medical illness. Med Hypotheses. 2015;84(6):602. https://doi.org/10.1016/j.mehy.2015.03.002.
Rybakowski JK, Abramowicz M, Szczepankiewicz A, Michalak M, Hauser J, Czekalski S. The association of glycogen synthase kinase-3beta (GSK-3β) gene polymorphism with kidney function in long-term lithium-treated bipolar patients. Int J Bipolar Disord. 2013;1(1):8.
Kishore BK, Ecelbarger CM. Lithium: a versatile tool for understanding renal physiology. Am J Physiol Renal Physiol. 2013;304(9):F1139–49. https://doi.org/10.1152/ajprenal.00718.2012.
Mancinelli R, Carpino G, Petrungaro S, Mammola CL, Tomaipitinca L, Filippini A, Facchiano A, Ziparo E, Giampietri C. Multifaceted Roles of GSK-3 in Cancer and Autophagy-Related Diseases. Oxid Med Cell Longev. 2017;2017:4629495. https://doi.org/10.1155/2017/4629495. Epub 2017 Dec 12.
Fotso Soh J, Almadani A, Beaulieu S, et al. The effect of atorvastatin on cognition and mood in bipolar disorder and unipolar depression patients: a secondary analysis of a randomized controlled trial. J Affect Disord. 2020;262:149–54. https://doi.org/10.1016/j.jad.2019.11.013.
Fotso Soh J, Beaulieu S, Trepiccione F, et al. A double-blind, randomized, placebo-controlled pilot trial of atorvastatin for nephrogenic diabetes insipidus in lithium users. Bipolar Disord. 2021;23(1):66–75.
Fotso Soh J, Torres-Platas SG, Beaulieu S, et al. Atorvastatin in the treatment of Lithium-induced nephrogenic diabetes insipidus: the protocol of a randomized controlled trial. BMC Psychiatry. 2018;18(1):227. https://doi.org/10.1186/s12888-018-1793-9.
Biondi B. The Normal TSH reference range: what has changed in the last decade? The J Clin Endocrinol Metab. 2013;98(9):3584–7. https://doi.org/10.1210/jc.2013-2760.
Goldstein D. Serum Calcium. In: Walker HK, Hall WD, Hurst JW, editors. Clinical methods: the history, physical, and laboratory examinations. Boston: Butterworths; 1990.
Modan M, Meytes D, Rozeman P, et al. Significance of high HbA1 levels in normal glucose tolerance. Diabetes Care. 1988;11(5):422–8.
Colantuoni E, Rosenblum M. Leveraging prognostic baseline variables to gain precision in randomized trials. Stat Med. 2015;34(18):2602–17. https://doi.org/10.1002/sim.6507.
Shawish MI, Bagheri B, Musini VM, Adams SP, Wright JM. Effect of atorvastatin on testosterone levels. Cochrane Database Syst Rev. 2021;1:CD013211. https://doi.org/10.1002/14651858.CD013211.pub2.
Ahmadi M, Amiri S, Pecic S, et al. Pleiotropic effects of statins: A focus on cancer. Biochim Biophys Acta Mol Basis Dis. 2020;1866(12):165968. https://doi.org/10.1016/j.bbadis.2020.165968.
Kavalipati N, Shah J, Ramakrishan A, Vasnawala H. Pleiotropic effects of statins. Indian. J Endocrinol Metab. 2015;19(5):554–62. https://doi.org/10.4103/2230-8210.163106.
Bonfrate L, Procino G, Wang DQ, Svelto M, Portincasa P. A novel therapeutic effect of statins on nephrogenic diabetes insipidus. J Cell Mol Med. 2015;19(2):265–82. https://doi.org/10.1111/jcmm.12422.
Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis. 1987;10(5):329–45.
Irving SA, Vadiveloo T, Leese GP. Drugs that interact with levothyroxine: an observational study from the thyroid epidemiology, audit and research study (TEARS). Clin Endocrinol. 2015;82(1):136–41. https://doi.org/10.1111/cen.12559.
Abbasinazari M, Nakhjavani M, Gogani S. The effects of simvastatin on the serum concentrations of thyroid stimulating hormone and free thyroxine in hypothyroid patients treated with levothyroxine. Iran J Med Sci. 2011;36(2):80–3.
Shulman KI, Sykora K, Gill SS, et al. New thyroxine treatment in older adults beginning lithium therapy: implications for clinical practice. Am J Geriatr Psychiatry. 2005;13(4):299–304. https://doi.org/10.1176/appi.ajgp.13.4.299.
Mansouri M, Pahlavani N, Sharifi F, et al. Dairy consumption in relation to hypertension among a large population of university students: the MEPHASOUS study. Diabetes Metab Syndr Obes. 2020;13:1633.
Pahlavani N, Khayyatzadeh SS, Banazadeh V, et al. Adherence to a dietary approach to stop hypertension (DASH)-style in relation to daytime sleepiness. Nat Sci Sleep. 2020;12:325.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.